Semaglutide (Novo Nordisk) in Obesity: ACTRN12626001033336 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2
Clinical phase
Recruiting
Recruitment status
113
Planned enrollment
Timing not reported
Primary-completion proxy
Executive view
ACTRN12626001033336 evaluates Semaglutide (Novo Nordisk) in Obesity. The disclosed sponsor is SIRONAX AUS PTY LTD, the design is Interventional, and the geographic footprint is Australia. The first listed primary endpoint is not reported, assessed over an unreported time frame.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for ACTRN12626001033336 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Obesity landscape. Drug & Asset MCP drug_fetch was queried for Semaglutide (Novo Nordisk), while Company & Deal Intelligence MCP organization_fetch was queried for SIRONAX AUS PTY LTD.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| ACTRN12626001033336 | Semaglutide (Novo Nordisk) | Phase 2 / Recruiting | SIRONAX AUS PTY LTD | Australia | Timing not reported | |
| NCT07777575 | PP03A | Phase 4 / Recruiting | Technische Universität München | Germany | Change in contractile thigh muscle volume (mL), as assessed by magnetic resonance imaging (MRI) From baseline to the end of treatment at 24 weeks | 2027-05-31 |
| NCT07772960 | Semaglutide (Novo Nordisk) | Phase 1 / Not yet recruiting | Yale University | United States | Alcohol use days 20 weeks | 2031-10-31 |
| NCT07759778 | Oliceridine fumarate | Phase 4 / Not yet recruiting | Second Affiliated Hospital of Wenzhou Medical University | Geography not reported | Effective Dose (ED50 and ED95) of Propofol Combined with Oliceridine for Gastroscope Insertion Within 3 minutes after gastroscope insertion | 2027-02-01 |
| NCT07757087 | Zenagamtide | Phase 1 / Recruiting | Novo Nordisk A/S | Netherlands, Denmark | Change in sleeping metabolic rate (SMR) Baseline (week 0) to week 12-26 | 2028-09-18 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
ACTRN12626001033336 is a Phase 2, recruiting study with 113 planned participants. Allocation is Randomised controlled trial, masking is Blinded (masking used), and the intervention model is not reported.
The primary endpoint is “not reported” over “not reported.” The retrieved endpoint description is: Percent change from baseline in total body fat mass[Dual-energy X-ray absorptiometry (DXA) Baseline and Week 24 post-baseline].
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 113 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Obesity. These records do not establish direct evidence for ACTRN12626001033336 unless the registration number matches.
Empagliflozin in CFRD: Efficacy and Safety of SGLT2 Inhibitor Therapy in Overweight and Obese Subjects With Cystic Fibrosis-related Diabetes: a Pilot Study
Phase 2/3; n=8; Continuous Glucose Monitor (CGM): Percentage of Time in Range 70-180mg/dL(Mean) = 78 percentage of time (Standard Deviation, 13.3); Continuous Glucose Monitor (CGM): Percentage of Time in Range 70-180mg/dL(Mean) = 85 percentage of time (Standard Deviation, 9.7) Source: https://clinicaltrials.gov/ct2/show/results/NCT06149793
Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity
Phase 4; n=79; Change in Stress Myocardial Perfusion Reserve on Cardiac MRI(Least Squares Mean): P-Value = 0.97; Change in Stress Myocardial Perfusion Reserve on Cardiac MRI(Least Squares Mean) = 0.154 ratio of mL/min/g per mL/min/g (95% Confidence Interval, -0.122 to 0.430) Source: https://clinicaltrials.gov/ct2/show/results/NCT04519164
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
Phase 1; n=254; Least-squares mean percentage weight change from baseline(Week 12; efficacy estimand) = 0.0 % ; Least-squares mean percentage weight change from baseline(Week 12; efficacy estimand) = 3.3 % Source: https://www.biospace.com/press-releases/corbus-pharmaceuticals-announces-positive-topline-data-from-canyon-1-study-of-daily-oral-crb-913-for-the-treatment-of-obesity
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Semaglutide (Novo Nordisk) is indexed as Recombinant polypeptide with GLP-1R biology and a global stage of Approved. The asset profile lists Novo Nordisk A/S as an originator or developer.
SIRONAX AUS PTY LTD is indexed in Australia. Develops molecule drug platform The record lists 1 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Semaglutide (Novo Nordisk) is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: ACTRN12626001033336
Protocol source: https://anzctr.org.au/ACTRN12626001033336.aspx
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.
Semaglutide (Novo Nordisk) in Obesity is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes the primary endpoint and Timing not reported the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
